The document "Global Report on Diabetes" by the World Health Organization (WHO) provides an in-depth analysis of diabetes as a global health challenge. It covers the rising prevalence of the disease, the associated risk factors, and the increasing burden on healthcare systems, particularly in low- a...nd middle-income countries. The report discusses strategies for preventing Type 2 diabetes, managing diabetes effectively, and reducing complications through integrated healthcare approaches. It emphasizes the need for global action, national policies, and collaboration across sectors to address diabetes and improve health outcomes worldwide.
more
Accessed online August 2018
Objective of this document: Present a summary of the administrative measures that serve as the basis for implementation of infection prevention and control (IPC)measures in the context of COVID-19
Ce document d'orientation est basé sur une recherche sur les activités des médias sociaux liées à l'utilisation des antibiotiques au niveau de l'UE, ainsi que sur une enquête sur les activités des médias sociaux des organisations partenaires de l'EAAD, principalement des organisations de pat...ients et de professionnels de la santé de l'UE. La recherche a montré qu'il existe déjà une certaine activité des médias sociaux sur l'utilisation prudente des antibiotiques et que quelques influenceurs potentiels apparaissent. De même, l'enquête menée auprès des partenaires de l'EAAD à l'échelle de l'UE a montré que les personnes interrogées deviennent actives sur les plateformes de médias sociaux.
more
The conditionality of this recommendation is largely driven by the current higher unit cost of pyrethroid-PBO ITNs compared
to pyrethroid-only LLINs and therefore the uncertainty of their cost-effectiveness. Furthermore, as PBO is less wash-resistant
than pyrethroids, its bioavailability declines ...faster over the three-year estimated life of an ITN; therefore, the added impact of
pyrethroid-PBO ITNs over that of pyrethroid-only LLINs may decline over time. The evidence comes from two sites in
eastern Africa with pyrethroid resistance and not from other geographies where transmission levels and vector characteristics
may vary. PBO acts by inhibiting certain metabolic enzymes, primarily oxidases, and so are likely to provide greater protection
than pyrethroid-only LLINs where mosquitoes display mono-oxygenase-based insecticide resistance mechanisms.
more
Версия 1.1
Дата: 25 января 2020 г.